Athletic Pubalgia
Conditions
Keywords
Chronic athletic pubalgia, Botulinum toxin, Groin pain, Adductor enthesopathy
Brief summary
Chronic athletic pubalgia is a frequent sport condition in which the effectiveness of medical treatment has not been proven. Intra-muscular injection of botulinum toxin A may have positive effects on pain in some chronic tendinitis. The investigators hypothesized that similar analgesic effect of intra-muscular botulinum toxin A may be observed in individuals with chronic AP. In the present study, the investigators aimed to describe the short-term evolution of pain and of activity limitations and quality of life, after an injection of the adductor longus with botulinum toxin A, in individuals with chronic AP, for whom medical and/or surgical treatments have failed.
Detailed description
The investigators included consecutive individuals with chronic athletic pubalgia for whom medical and/or surgical treatments have failed and who were treated with an intra-muscular injection of botulinum toxin A under ultrasound guidance. Participants were assessed 50 days after injection for pain using a numerical rating scale (NRS) (0, no pain, and 100, maximal pain) and for activity limitations and quality of life using the Copenhagen Hip and Groin Outcome Score (HAGOS) (0, worse outcome, and 100, most favorable outcome). Participants were also asked to self-report adverse events.
Interventions
OTHERBotulinum Toxin A
100 UI IM in the adductor longus
Sponsors
URC-CIC Paris Descartes Necker Cochin
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* chronic AP * symptom duration ≥ 3 months * consistent clinical and magnetic resonance imaging findings according to the clinician * failure of medical and/or surgical treatments with persistent pain and inability to return to play * treatment with an intra-muscular injection of botulinum toxin A injection
Exclusion criteria
* age under 18 years * ongoing pregnancy or breastfeeding * treatments by anticoagulants * muscular disorder (e.g. polymyositis, myopathy or other neuromuscular conditions) * guardianship or curatorship * individuals who had received botulinum toxin type A treatment for less than one year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numerical rating scale | 50 days | Mean pain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HAGOS score | 50 days | Mean HAGOS total score |
Countries
France
Outcome results
None listed